ClinicalRM Awarded BARDA Contract to Support the "Medical Countermeasures Clinical Studies Network"


Company News Release

Clinical Research Management, Inc. announced today it was awarded a contract by the Biomedical Advanced Research and Development Authority.

Clinical Research Management, Inc. (ClinicalRM) – a full-service Contract Research Organization (CRO) providing support for basic and applied research, clinical trials, and regulatory support – announced today it was awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). With this contract award ClinicalRM becomes part of a clinical studies network being established by BARDA to support development of vaccines, drugs, and diagnostics, known as medical countermeasures, needed to protect health and potentially save lives in public health emergencies.  The network will provide clinical services in support of adequate and well-controlled phase 1 through 4 clinical trials or trials during a public health emergency, and will support the evaluation of Chemical, Biological, Radiological, Nuclear, Pandemic Influenza and Emerging Infectious Disease medical countermeasures.     

ClinicalRM is one of only 5 other companies to be awarded this contract. 100% of the total costs of the program will be financed with Federal money.  It is a 2-year contract with three 1-years option BARDA may exercise. The total contract ceiling for 5-year program is $100 million.  

Dr. David Hoover, ClinicalRM's Program Director, stated, "We look forward to working with BARDA to evaluate new treatments for medical conditions that could have devastating impacts on many people. New treatments are vitally important for improved management of infectious diseases and exposures to a broad range of toxic agents." 

Dr. Alan Braverman, Vice President of Clinical Operations of ClinicalRM, noted that ClinicalRM with its longstanding tradition of creating meaningful partnerships with Government, industry and academia in infectious disease trials is honored to be selected and looks forward to being a key contributor to BARDA in achieving its mission.

Victoria Tifft, CEO of ClinicalRM, stated, "ClinicalRM is proud to engage in this critical work with BARDA. The award of this contract allows us to continue to build strong and meaningful partnerships with the Government, industry, and academia to combat a variety of potential national threats."

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.